Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.

23 Jan 2014

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.

23 Jan 2014

New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

Patrys Limited, a clinical stage biotechnology company is pleased to announce the publication of a new scientific article regarding its product PAT-SC1 in the Oncology Reports journal. The article is currently available online and will be included in a future print edition of the journal.

22 Jan 2014

Mutation in bone cells may cause acute myeloid leukemia: Study

Acute myeloid leukemia is a blood cancer, but for many patients the cancer may originate from an unusual source: a mutation in their bone cells.

21 Jan 2014

Kolltan Pharmaceuticals announces treatment of first cancer patient with KTN3379

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.

21 Jan 2014

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

A research conducted by the Centre for Plant Biotechnology and Genomics (UPM-INIA) and led by Araceli Díaz Perales has studied the allergy to peach, the most common food allergy, and the Pru p 3 protein. As a result of this research work, they have developed three hypoallergenic variants of this protein. All can be good candidates for the usage of specific immunotherapy for peach allergy and also can be used as a vaccine.

20 Jan 2014

TSRI scientists use new technique to discover two antibodies that protect human cells from cold virus

Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find-relatively quickly and cheaply-antibodies that have a desired effect on cells. The TSRI scientists used the technique to discover two antibodies that protect human cells from a cold virus.

20 Jan 2014

Research roundup: Nursing home transitions; the impact of raising Medicare premiums; workers' views of job-based insurance

Each week, KHN compiles a selection of recently released health policy studies and briefs.

20 Jan 2014

New discovery provides insight into body's rejection process during transplantation

In 2009, the first face transplant was performed at Brigham and Women's Hospital (BWH), and lead surgeon, Dr. Bohdan Pomahac has been pioneering the procedure since.

20 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute's Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.

16 Jan 2014

EU-sponsored TumAdoR project targets relationship between immune system and cancer growth

A multinational set of seven teams is banding together to develop a drug that may potentially fight many different cancers through an antibody that would work within the body's metabolic system.

16 Jan 2014

UMMS researchers commissioned by Alpha-1 Project to develop PiZ antibody

Researchers at the University of Massachusetts Medical School (UMMS) have been commissioned by the Alpha-1 Project (TAP) to develop a PiZ antibody. The antibody will be used to track the presence of mutant alpha-1 PiZ protein in human blood serum, an essential tool in testing potential therapies for Alpha-1 Antitrypsin Deficiency (Alpha-1).

13 Jan 2014

Scientists discover genetic signature mechanism in immune system as driving force for childhood leukaemia

Scientists have discovered a genetic signature that implicates a key mechanism in the immune system as a driving force for a type of childhood leukaemia.

13 Jan 2014

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models.

10 Jan 2014

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced interim data from a Phase 3 cholera challenge study of its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo.

10 Jan 2014

Researchers deploy potential new weapon against HIV

Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV - a combination therapy that targets HIV-infected cells that standard therapies cannot kill.

10 Jan 2014

Zymeworks, ImClone Systems partner to develop novel bi-specific antibody oncology therapeutics

Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody oncology therapeutics using Zymeworks' proprietary Azymetric platform. Bi-specific antibodies have the potential to provide improved outcomes for patients by simultaneously targeting two tumor associated antigens to induce a synergistic therapeutic response.

9 Jan 2014

ProteinSimple introduces revolutionary re-invention of Western blot

ProteinSimple today introduced Wes, another revolutionary re-invention of the Western blot. Wes is the bold evolution of the popular Simple Western family of instruments, delivering simplicity and performance like no product before it. With just 30 minutes of sample prep, Wes will analyze up to 25 samples in under 3 hours and he will do it all for less than the price of a high-end Western imager.

From ProteinSimple 8 Jan 2014

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.

8 Jan 2014

Antibody News and Research

Further Reading

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

Mutation in bone cells may cause acute myeloid leukemia: Study

Kolltan Pharmaceuticals announces treatment of first cancer patient with KTN3379

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

TSRI scientists use new technique to discover two antibodies that protect human cells from cold virus

Research roundup: Nursing home transitions; the impact of raising Medicare premiums; workers' views of job-based insurance

New discovery provides insight into body's rejection process during transplantation

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Biothera enhances innate immune responses to Imprime PGG drug candidate

EU-sponsored TumAdoR project targets relationship between immune system and cancer growth

UMMS researchers commissioned by Alpha-1 Project to develop PiZ antibody

Scientists discover genetic signature mechanism in immune system as driving force for childhood leukaemia

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

Researchers deploy potential new weapon against HIV

Zymeworks, ImClone Systems partner to develop novel bi-specific antibody oncology therapeutics

ProteinSimple introduces revolutionary re-invention of Western blot

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

Monoclonal Antibody Manufacturing Trends eBook eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News